Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection
Annals of Internal MedicinePublished 18 September 2007
Lillian Sung, Paul C. Nathan, Shabbir M.H. Alibhai, George Tomlinson, Joseph Beyene
Citations189
SJR quartileQ1
SJR score3.38
SNIP3.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Whether prophylactic CSFs decrease all-cause and infection-related mortality, as well as infections and febrile neutropenia, more than do placebo or no therapy in patients with cancer and patients undergoing SCT is sought.
Abstract
Prophylactic CSFs may have little or no effect on mortality but do decrease rates of infection in patients receiving cancer chemotherapy or those undergoing SCT.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
BiometricsThe Measurement of Observer Agreement for Categorical Data
78,934 Citations1977J. Richard Landis, Gary G. Koch
A general statistical methodology for the analysis of multivariate categorical data arising from observer reliability studies is presented and tests for interobserver bias are presented in terms of first-order marginal homogeneity and measures of interob server agreement are developed as generalized kappa-type statistics.
Controlled Clinical TrialsMeta-analysis in clinical trials
39,316 Citations1986Rebecca DerSimonian, Nan M. Laird
This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Controlled Clinical TrialsAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
17,565 Citations1996Alejandro R. Jadad, R Andrew Moore +5 more
An instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research is described and its use to determine the effect of rater blinding on the assessments of quality is described.
The LancetImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
4,808 Citations1999David Moher, Fadi Hammal +4 more
This report hopes this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.
Journal of Clinical Oncology2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
1,644 Citations2006Thomas J. Smith, James Khatcheressian +20 more
BMJEmpirical assessment of effect of publication bias on meta-analyses
1,418 Citations2000Alex J. Sutton
New England Journal of MedicineReduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
1,398 Citations1991Jeffrey Crawford, Howard Ozer +14 more
A randomized clinical trial to test the hypothesis that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer and the clinical implications.
Journal of Clinical Oncology2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
1,049 Citations2000Howard Ozer, Jamés O. Armitage +12 more
European Journal of CancerRecombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
545 Citations1993V. Trillet-Lenoir, J. Green +9 more
Annals of Internal MedicineMeta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients
497 Citations2005Anat Gafter‐Gvili, Abigail Fraser +2 more
This meta-analysis summarizes 95 randomized trials of antibiotic prophylaxis in 9283 afebrile neutropenic patients with conditions such as hematologic cancer and found that fluoroquinolones reduced the risk for fever, infections, and all-cause and infection-related mortality.
New England Journal of MedicineRecombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer
494 Citations1991John Nemunaitis, Susan N. Rabinowe +14 more
In patients undergoing autologous bone marrow transplantation for lymphoid neoplasia, rhGM-CSF significantly lessens morbidity and further studies will be required to establish its optimal dosage and schedule of administration.
Journal of Clinical OncologyAdults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
486 Citations1996Ian Magrath, Magdalena Adde +10 more
EFS in high-risk patients has been markedly improved by including IVAC in protocol 89-C-41, and excellent results can be achieved with only four cycles of therapy, and GM-CSF was not beneficial.
Journal of Clinical OncologyFirst and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
481 Citations2005Charles L. Vogel, Marek Z. Wojtukiewicz +6 more
First and subsequent cycle use of pegfilgrastim with a moderately myelosuppressive chemotherapy regimen markedly reduced febrile neutropenia, febrian neutropania-related hospitalizations, and IV anti-infective use.
New England Journal of MedicineGranulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
455 Citations1995Richard M. Stone, Deborah Berg +8 more
GM-CSF, in the dose and schedule used, does not stimulate the regrowth of leukemia, but it also does not decrease the severe myelosuppressive consequences of initial chemotherapy or improve the response rate in patients 60 years of age or older with primary AML.
BloodA randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)
448 Citations1995JM Rowe, J. W. Andersen +8 more
It appears that GM-CSF is safe and efficacious for adult patients greater than 55 to 70 years of age with AML; its major impact is in reducing the duration of neutropenia and therapy-related mortality and morbidity.
Journal of Clinical OncologyAmerican Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
445 Citations1994
Therapeutic initiation of CSFs in addition to antibiotics at the onset of febrile neutropenia should be reserved for patients at high risk for septic complications and CSF use in patients with myelodysplastic syndromes may be reasonable if they are experiencing neutropenic infections.
BloodAttempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
437 Citations2001Anthony H. Goldstone, Alan K. Burnett +4 more
In an attempt to improve induction chemotherapy for older patients with acute myeloid leukemia (AML), patients were randomized to 1 of 3 induction treatments for 2 courses of DAT, ADE, or MAC and the remission rate in the DAT arm was significantly better than ADE or MAC.
BloodGranulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
411 Citations1992Ruth Pettengell, Howard Gurney +7 more
Overall, patients randomized to receive G-CSF achieved a greater dose intensity than control patients, but this did not result in significant differences in drug toxicity (other than neutropenia), intravenous antibiotic usage, or hospitalization between the two groups.
New England Journal of MedicineEffect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute Leukemia
395 Citations1990Ryuzo Ohno, Masao Tomonaga +18 more
It appears that recombinant human granulocyte CSF is safe in acute leukemia, accelerating neutrophil recovery and thereby reducing the incidence of documented infection without affecting the regrowth of leukemic cells.
BloodA Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia
332 Citations1997Gerhard Heil, Dieter Hoelzer +10 more
In conclusion, filgrastim is safe in that it had no negative impact on the prognosis of the AML patients and effectively reduced the duration of neutropenia, leading to significant clinical benefits by reducing theduration of fever; requirement for parenteral anti-infectives, specifically amphotericin B; and theurations of hospitalization.
BloodGranulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
331 Citations1992Ruth Pettengell, Howard Gurney +7 more
New England Journal of MedicineA Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia
312 Citations1995Hervé Dombret, Claude Chastang +10 more
The administration of lenograstim after chemotherapy for AML did not decrease the mortality rate at eight weeks among patients over the age of 65 years, and the rate of complete remission was significantly higher in the lenogirastim group than in the placebo group.
BloodA Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
310 Citations1998John E. Godwin, Kenneth J. Kopecky +6 more
PubMedA randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
270 Citations1998Richard A. Larson, Richard K. Dodge +10 more
Children and adults with untreated ALL who received intensive chemotherapy for ALL benefited from G-CSF treatment, but its use did not markedly affect the ultimate outcome.
Journal of Clinical OncologyHigher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry
261 Citations2004Mary Eapen, Mary M. Horowitz +5 more
These data suggest poorer outcomes after PBSC compared with BM transplantation in children after adjusting for relevant risk factors, and prospective clinical trials are required to determine their appropriate role.
The American Journal of MedicineProphylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis
223 Citations2002Gary H. Lyman, Nicole M. Kuderer +1 more
In this meta-analysis, recombinant colony-stimulating factors were effective in reducing the risk of febrile neutropenia and documented infection associated with several malignancies and dose-intensive treatment regimens.
Journal of Clinical OncologyClinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
196 Citations1991Lawrence D. Kaplan, James O. Kahn +8 more
Thirty patients with human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma receiving chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone were randomized to receive either subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) or no additional therapy.
Journal of Clinical OncologyLess Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98
192 Citations2006Ursula Creutzig, Martin Zimmermann +9 more
Overall results were improved by neither the administration of G-CSF nor by cycle therapy; however, the latter was easier to perform.
Journal of Clinical OncologyTreatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
191 Citations2003Olle Ringdén, Myriam Labopin +10 more
After BMT, platelet engraftment was delayed, and GVHD and TRM were increased, and survival and LFS were reduced, suggesting that G-CSF should not be given shortly after BMT.
Journal of Clinical OncologyChemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
189 Citations1995Paul A. Bunn, John Crowley +8 more
GM-CSF, as delivered in this study, should not be included with concurrent chemoradiotherapy treatment programs for limited-stage SCLC and the simultaneous use of hematopoietic colony-stimulating factors (CSFs) and cheMoradiotherapy should be performed only in experimental settings.
Journal of Clinical OncologyPrevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study
185 Citations2005Johanna N.H. Timmer-Bonte, Theo M. de Boo +10 more
Primary G-CSF prophylaxis added to primary antibiotic prophYLaxis is effective in reducing FN and infections in SCLC patients at the risk of FN with the first cycle of CDE chemotherapy.
Journal of Clinical OncologyGranulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.
180 Citations1995TR Klumpp, Kenneth F. Mangan +3 more
Administration of G-CSF in the posttransplant period accelerates the rate of neutrophil engraftment, shortens the duration of hospitalization, and reduces the number of days on nonprophylactic antibiotics in patients who receive autologous PBSC with or without autOLOGous bone marrow following high-dose therapy.
The LancetPlacebo-controlled phase III trial of lenograstim in bone-marrow transplantation
172 Citations1994Christian Gisselbrecht, H. G. Prentice +12 more
In patients undergoing autologous or allogeneic BMT for neoplastic disease, lenograstim significantly reduced duration of neutropenia and led to earlier hospital discharge and there was no significant toxicity ascribed to lenogsrastim.
Annals of Internal MedicineGranulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease
172 Citations1992Subhash C. Gulati, Charles L. Bennett
Administration of GM-CSF was associated with acceleration of myeloid and platelet recovery and was cost effective in the treatment of patients with relapsed Hodgkin disease who received intensive chemotherapy.
BloodRandomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments]
171 Citations1993H Gerhartz, M. Engelhard +8 more
Data show that rhGM-CSF is well tolerated in most patients with NHL, significantly reduces infection, and improves response, and no difference in survival has been seen after 1 year.
Journal of Clinical OncologyCHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma
168 Citations2003Jeanette K. Doorduijn, Bronno van der Holt +14 more
In elderly patients with aggressive non-Hodgkin's lymphoma, G-CSF improved the RDI of CHOP, but this did not lead to a higher complete response rate or better overall survival.
New England Journal of MedicineHuman Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
167 Citations1997Ching‐Hon Pui, James M. Boyett +9 more
G-CSF treatment had some clinical benefit in children who received induction chemotherapy for acute lymphoblastic leukemia, but it did not reduce the rate of hospitalization for febrile neutropenia, prolong survival, or reduce the cost of supportive care.
PubMedRandomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
163 Citations1997Pier Luigi Zinzani, Enzo Pavone +17 more
The data show that VNCOP-B is a feasible and effective regimen in elderly HG-NHL patients, and that the use of G-CSF reduces infection and neutropenia rates without producing any significant modifications to the dose intensity, CR rate, and relapse-free survival curve.
Cochrane Database of Systematic ReviewsGranulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma
156 Citations2008Julia Bohlius, Christine Herbst +3 more
G- CSF and GM-CSF, when used as a prophylaxis in patients with malignant lymphoma undergoing conventional chemotherapy, reduce the risk of neutropenia, febrile neutropania and infection and improve quality of life, adherence to treatment protocol, tumour response, freedom from treatment failure (FFTF) and overall survival (OS).
BloodUse of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
148 Citations2005Sergio Amadori
It is concluded that although priming with G- CSF can improve the CR rate, the use of G-CSF during and/or after chemotherapy has no effect on the long-term outcome of AML in older patients.
Journal of Clinical OncologyEffects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
147 Citations1998William P. Steward, Joachim von Pawel +11 more
Dose intensification of V-ICE to a 3-week schedule in SCLC is not associated with increased toxicity, but appears to improve survival significantly, and future studies should aim to deliver chemotherapy in maximal-tolerated dose-intensities.
PubMedA placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
147 Citations1998Francis Witz, Alain Sadoun +19 more
Administration of Granulocyte-macrophage colony-stimulating factor, concomitantly with chemotherapy and thereafter during induction course in AML, shortened the time to neutrophil recovery, but did not improve the CR rate in patients aged 55 to 75, although DFS and OS were significantly prolonged in patients ages 55 to 64 treated with GM-CSF.
Journal of Clinical OncologyFilgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
146 Citations1998Sophie D. Fosså, Stuart Kaye +10 more
During combination chemotherapy in patients with malignant germ cell tumors, the routine use of filgrastim significantly improved the delivery of the planned treatment schedule without effect on failure-free or overall survival.
BloodConcomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial
143 Citations1995Oliver G. Ottmann, D. Hoelzer +8 more
Adult ALL patients appear to benefit by the simultaneous administration of G-CSF with induction chemotherapy because of a significant reduction in the duration of neutropenia, a trend to fewer infections, and a more rapid completion of chemotherapy.
Journal of Clinical OncologyEffect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
139 Citations1995K H Chi, Chen‐Hsin Chen +7 more
GM-CSF can significantly reduce the severity and duration of chemotherapy-induced oral mucositis after PFL chemotherapy, and these beneficial effects continued into the second cycle of P FL chemotherapy after crossover to no GM- CSF.
BloodFludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
139 Citations2006Donald Milligan, Keith Wheatley +3 more
It is indicated that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.
BloodA randomized phase-III study of the efficacy of granulocyte colony- stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group
137 Citations1996Karl Welte, Alfred Reiter +5 more
R-metHuG-CSF administered prophylactically in the interval between chemotherapy courses significantly reduced febrile neutropenia, culture-confirmed infections, and duration of intravenous antibiotic administration and allowed for tighter adherence to the treatment schedule.
Journal of Clinical OncologyRandomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.
136 Citations1994G Spitzer, Douglas R. Adkins +8 more
Despite faster neutrophil recovery and shortened duration of hospitalization with GFs administered after PBSC transplantation, the measured clinical variables of febrile days, septic episodes, and transfusion requirements were similar between the study arms.
The LancetHuman recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial
133 Citations1990R Powles, C. W. Smith +6 more
The GM-CSF group had lower haemoglobin concentrations and platelet counts and higher plasma urea, creatinine, and bilirubin than the placebo group, and the duration of hospital stay was the same for both patient groups.
Journal of Clinical OncologyCan cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
129 Citations1995Penella J. Woll, Jackie Hodgetts +4 more
The G-CSF group received a significantly higher dose-intensity than the control group, with the greatest difference in the first three cycles, and had a better 2-year survival rate than controls.
Journal of Clinical OncologyValue of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
128 Citations1997Bob Löwenberg, M. Boogaerts +15 more
Priming of AML cells to the cytotoxic effects of CT by the use of GM-CSF during CT or accelerating myeloid recovery by theUse of GM -CSF after CT does not significantly improve treatment outcome of young and middle-aged adults with newly diagnosed AML.
Journal of Clinical OncologyLenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
124 Citations1995B Chevallier, P. Chollet +8 more
Lenograstim is safe and effective to reduce morbidity associated with FEC-HD neoadjuvant chemotherapy in inflammatory breast cancer and was associated with a statistically significant reduced incidence of microbiologically documented infections, and a decreased need for rehospitalizations for infectious events and antibiotic use.
PubMedPhase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
124 Citations1995John Nemunaitis, C Rosenfeld +8 more
RhGM-CSF is well tolerated and reduces post-transplant morbidity in patients undergoing HLA-identical allogeneic BMT, and no differences in platelet recovery, erythrocyte recovery, incidence of veno-occlusive disease, GVHD severity, relapse or survival were observed.
Journal of Clinical OncologyLow-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
122 Citations1997I. Grant McQuaker, A Hunter +4 more
Low-dose filgrastim significantly reduces neutrophil engraftment time post-PBSCT and also reduces in-patient stay and costs, which makes it economically viable for patients who are undergoing high-dose chemotherapy.
Journal of Clinical OncologyGranulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
122 Citations1996R Zittoun, Stefan Suciu +10 more
GM-CSF administered during induction treatment of AML with a DNR/Ara-C combination did not provide any clinical benefit and there was a significant decrease in the CR rate with more persistent leukemia when GM- CSF was administered during the hypoplastic phase after the chemotherapy courses.
Journal of Clinical OncologyMeta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation
121 Citations2006A. Dekker, Sean R. Bulley +4 more
CSFs were associated with a small reduction in the risk of documented infections but did not affect infection or treatment-related mortality.
Journal of Clinical OncologyProphylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials
120 Citations2004Lillian Sung, Paul C. Nathan +3 more
CSFs were associated with a 20% reduction in febrile neutropenia and shorter duration of hospitalization; however, CSFs did not reduce infection-related mortality.
Leukemia & lymphoma/Leukemia and lymphomaOpen-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
114 Citations2003Andrew Grigg, Philippe Solal‐Céligny +3 more
Pegfilgrastim was well tolerated with a safety profile similar to daily fil grastim and once per chemotherapy cycle administration of pegfilgrASTim was comparable to filgrastIM in this clinical setting.
BiometricsRatio Estimates, the Delta Method, and Quantal Response Tests for Increased Carcinogenicity
113 Citations1993Gayle Bieler, Rick L. Williams
Although the delta method approach is slightly more computationally intensive, small-sample simulations indicate that it has superior operating characteristics over the Poly-3 trend test of Bailer and Portier when background tumor incidence rates are low and survival patterns differ markedly across treatments.
BloodRecombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double- blind placebo-controlled trial
107 Citations1992NC Gorin, B Coiffier +8 more
After ABMT with purged or unpurged marrow, rhu GM-CSF (E coli) significantly reduces neutropenia duration and hospitalization stay, and a positive causative relation between the study drug and/or its mode of application with an increased toxicity cannot be deduced from the experiences in this study.
BloodGranulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia — A Randomized Phase-III Study
102 Citations1997Klaus Geißler, Elisabeth Koller +14 more
Journal of Clinical OncologyRandomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
100 Citations1994Rolf A. Stahel, L.M. Jost +7 more
The role of filgrastim given as an adjunct to ABMT in accelerating neutrophil recovery, as well as in reducing treatment-related morbidity and overall duration of the treatment procedure, is supported.
PubMedA double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
98 Citations1991Elisabeth G.E. de Vries, Bonne Biesma +5 more
It is concluded that a dose of 3 and 6 micrograms/kg/day GM-CSF reduces the severity of neutropenia and thrombocytopenia after carboplatin-cyclophosphamide after ovarian cancer stage III or IV.
BloodA randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation
93 Citations2000Michael R. Bishop, Stefano Tarantolo +10 more
BloodA randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation
92 Citations2000Michael R. Bishop, Stefano Tarantolo +10 more
The administration of filgrastim appears to be a safe and effective supportive-care measure following allogeneic BSCT.
BloodA controlled trial of recombinant human granulocyte-macrophage colony- stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma
92 Citations1992Hartmut Link, MA Boogaerts +8 more
It is concluded that continuous infusion of rhuGM-CSF after ABMT accelerates the regeneration of granulocytes and reduces the number of bacterial infections.
Leukemia & lymphoma/Leukemia and lymphomaPlacebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration
90 Citations1997Christian Gisselbrecht, Corinne Haïoun +13 more
It is suggested that patients treated with a chemotherapy regimen that induces severe neutropenia can benefit from treatment with lenograstim, and may permit further dose escalation of the chemotherapeutic regimen used.
BloodRecombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell- depleted bone marrow transplantation
90 Citations1992T. de Witte, Aloïs Gratwohl +8 more
It is shown that rhGM-CSF significantly increases neutrophil and monocyte counts during periods of 6 to 10 days in the second and third week after BMT, which is a shortened period until myeloid cell recovery after transplantation.
Journal of Clinical OncologyGranulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques
83 Citations2000Jean‐Luc Harousseau, Brigitte Witz +14 more
G-CSF should be administered routinely after ICC to reduce the duration of neutropenia and hospitalization, and did not seem to significantly increase the feasibility of this two-course program or modify overall outcome.
PubMedRandomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.
79 Citations1993David C. Linch, H Scarffe +8 more
A multicentre, randomised vehicle-controlled single-blind dose ranging trial of intravenous recombinant granulocyte colony-stimulating factor (rhuG-CSF) administration after BMT has been performed in 121 patients with non-myeloid malignancies and found a trend to less antibiotic use and the median time in hospital was markedly reduced.
LeukemiaGranulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)
76 Citations1999Xavier Thomas, Pierre Fenaux +19 more
GM-CSF might marginally increase efficacy of sequential chemotherapy without increasing its toxicity in the absence of any detected relationship between this effect and observed leukemic cell recruitment into the S phase of cell cycle before the second sequence.
Journal of Clinical OncologyEscalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.
76 Citations1995Christopher J. Logothetis, L D Finn +7 more
The use of the hematopoietic growth factor rhGM-CSF did not result in an increased dose-intensity of escalated MVAC, and the inability to increase the dose- intensity of MVAC further was a result of nonhematologic side effects of the chemotherapy.
Journal of Clinical OncologyEfficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
76 Citations1995B. Bui, B Chevallier +8 more
Lenograstim significantly improved hematologic tolerance in patients treated with the MAID chemotherapy regimen and, therefore, allowed optimal adhesion to the theoretic doses planned for up to six cycles.
British Journal of HaematologyG‐CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial
75 Citations1997David C. Linch, Donald Milligan +9 more
Data indicate that lenograstim significantly accelerated myeloid recovery after PBSCT and shortened the duration of hospital stay.
Journal of Clinical OncologyAddition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
75 Citations2003Paola Papaldo, Massimo Lopez +18 more
EC is active and well tolerated in patients with early breast cancer, and G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity.
LeukemiaEffect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
75 Citations2007Xavier Thomas, Emmanuel Raffoux +18 more
Bone Marrow TransplantationG-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV
74 Citations2003Mats Remberger, N Naseh +5 more
G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II–IV acute GVHD, but not transplant-related mortality, according to multivariate analysis.
BloodRecombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell- depleted bone marrow transplantation
74 Citations1992T De Witte, A Gratwohl +8 more
British Journal of CancerGranulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer
70 Citations1994Andrea Ardizzoni, M. Venturini +13 more
This randomised trial indicates that GM-CSF is useful for chemotherapy acceleration and is a moderately dose-intensive regimen that can be administered in an outpatient clinic and is associated with a high objective response.
British Journal of HaematologyEfficacy of granulocyte colony‐stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study
67 Citations2002Kensuke Usuki, Akio Urabe +29 more
Prophylactic administration of G‐CSF after remission induction therapy for acute myelogenous leukaemia is safe and useful even in patients without infection on completing chemotherapy.
British Journal of HaematologyHAEMATOPOIETIC GROWTH FACTORS IN CHILDREN WITH NEUTROPENIA
64 Citations2002Thomas Lehrnbecher, Karl Welte
Despite early antibiotic therapy, fever in the neutropenic host is the most important determinant for modi-cation of therapy as well as one of the most common reasons for hospitalization (Pizzo, 1981, 1993).
BloodControlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen–matched related donors
63 Citations2001Donna Przepiorka, Terry L. Smith +7 more
It can be concluded that the administration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neutrophil recovery.
BloodProphylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
60 Citations2006Thomas Lehrnbecher, Martin Zimmermann +4 more
G-CSF did not decrease the incidence of febrile neutropenia, microbiologically documented infections, and infection-associated mortality in children with de novo AML, and both groups had similar 5-year event-free survival.
British Journal of CancerRecombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost
57 Citations1998Siow Ming Lee, John Radford +7 more
It is suggested that after HDCT and PBPC rescue, the use of G-CSF leads to more rapid haematological recovery periods and is associated with a more predictable and shorter hospital stay.
Journal of Clinical OncologyDose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
57 Citations1994John Hamm, Joan H. Schiller +5 more
Journal of Clinical OncologyRandomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study.
56 Citations1998Joseph Laver, M Amylon +5 more
PubMedMarginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT.
56 Citations1998Yoshifumi Kawano, Yoichi Takaue +21 more
Evaluating the effectiveness of exogenous granulocyte colony-stimulating factor treatment in accelerating hematopoietic recovery after PBSCT concluded that the clinical benefit of 1 day earlier recovery of granulocytes could be offset by the delayed recovery of platelets.
Epsilon: Revista de la Sociedad Andaluza de Educación Matemática "Thales"Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
56 Citations1995N Schmitz, P Dreger +8 more
R-metHuG-CSF was well tolerated without any serious side-effects in patients with malignant lymphoma, haematopoietic recovery after high-dose chemotherapy and autologous bone marrow transplantation (BMT) and was compared between patients randomised to receive 10 or 30 micrograms/kg/day of r-met HuG- CSF (filgrastim) or no growth factor.
Journal of Clinical OncologyReceived dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
55 Citations1994David Miles, O Fogarty +8 more
In this randomized trial, G-CSF significantly decreased dose reductions due to neutropenia, however, administration of G- CSF did not decrease dose reductions or treatment delays to a level that would allow an increase in received dose-intensity.
British Journal of HaematologyImpact of granulocyte colony‐stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review
55 Citations2003Julia Bohlius, Marcel Reiser +2 more
There is no evidence that G‐ CSF/GM‐CSF improved CR and OS in this clinical setting.
British Journal of HaematologyRecombinant human granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double‐blind, placebo‐controlled trial
54 Citations1992Asim Khwaja, D C Linch +16 more
A multicentre randomized double‐blind placebo controlled trial in patients with poor prognosis malignant lymphoma receiving an identical high‐dose combination chemotherapy regimen with ABMT confirmed in a randomized trial that GM‐CSF accelerates neutrophil but not platelet recovery following ABMT.
Journal of Clinical OncologyRandomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.
53 Citations1996Leonard H. Wexler, Linda Weaver‐McClure +6 more
The costs and increased toxicities associated with the use of this agent are not justified by its minimal clinical benefit for regimens of this level of intensity and GM-CSF also does not reduce the need for hospitalization or the incidence of febrile neutropenia and infectious complications.
Journal of Clinical OncologyRandomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
52 Citations1996Sarah E. Jones, M W Schottstaedt +10 more
GM-CSF significantly enhanced ANC recovery after FAC chemotherapy; it decreased the incidence and duration of associated neutropenia and moderately increased the dose-intensity of adjuvant chemotherapy.
Journal of Clinical OncologyUse of Recombinant Human Granulocyte Colony-Stimulating Factor to Increase Chemotherapy Dose-Intensity: A Randomized Trial in Very High-Risk Childhood Acute Lymphoblastic Leukemia
52 Citations2000Gérard Michel, Judith Landman‐Parker +16 more
G-CSF can increase CDI in high-risk childhood ALL, but its effects depend on the chemotherapy regimen given before G- CSF administration, and a higher CDI did not improve disease control.
British Journal of CancerCODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
51 Citations1997M. Fukuoka, N Masuda +11 more
RhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs and a significant improvement in survival.
Lung CancerRole of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis
50 Citations2002Thierry Berghmans, M Paesmans +4 more
The published data do not support the routine use of haematological colony-stimulating factors in the treatment of small-cell lung cancer (SCLC) and a reduced survival was associated with concentrated chemotherapy.
Journal of Clinical OncologyHuman Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study
50 Citations2003John A. Heath, Peter G. Steinherz +10 more
Children with high-risk acute lymphoblastic leukemia do not appear to benefit from prophylactic G-CSF, and there were no differences in 6-year EFS or OS.
CancerGranulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study
49 Citations1995Stefan Burdach, Markus Müschenich +5 more
Granulocytemacrophage‐colony stimulating factor (GM‐CSF) is a hematopoietic growth factor that increases the number of circulating neutrophils as demonstrated in adults.
Bone Marrow TransplantationLenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial
46 Citations2004Norbert Schmitz, Per Ljungman +16 more
The administration of lenograstim after HDT and ASCT significantly reduces the incidence of microbiologically defined infections until neutrophil recovery and leads to less use of antibiotics and earlier discharge from hospital.
Journal of Clinical OncologyProspective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
43 Citations1997Philippe Moreau, D Fière +10 more
GM-CSF after HDM without SCT is feasible and significantly shortens neutropenia with a trend toward reduction of hospitalization duration, but does not significantly reduce the morbidity and mortality of such therapy.
…